On Demand 2016 Early Recognition and Effective Management of Hereditary Angioedema (not for CME credit)

Price: FREE

This symposium will utilize an interactive, case- and discussion-based format to provide attendees with cutting-edge medical education in a peer-to-peer discussion format. The program will engage health care providers by linking discussion of the latest scientific data with its application in the clinical setting.

This session capture is offered free of charge (non-credit) courtesy of our commercial supporter, Salix Pharmaceuticals.

This activity is supported by educational grants from Salix Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC, and Shire.

Learning Objectives

Objective 1: Utilize guideline-based clinical criteria and testing for the accurate diagnosis of patients with HAE.
Objective 2: Review the underlying enzymatic pathways involved in the pathogenesis of HAE.
Objective 3: Describe available therapies used to treat acute attacks of HAE and discuss available therapies for short- and long-term prophylaxis in patients with HAE. 

Additional information
Michael E. Manning, MD, FACAAI, Moderator – Consultant/Advisor: CSL Behring, Dyax, Genentech, Shire
Bruce L. Zuraw, MD, FACAAI – Consultant/Advisor: Biocryst, Novartis, CSL Behring, Sanofi, Shire, Dyax, Genentech, Alnylan, Arrowhead, Isis
Marc A. Riedl, MD, MS – Consultant/Advisor: Baxter, Biocryst, CSL Behring, Grifols, Arrowhead, Ionis, Salix, Shire; Speaker: Baxter, CSL Behring, Dyax, Salix, Shire; Supported/ Contracted Research: Amgen, Biocryst, CSL Behring, Dyax, Ionis, Pharming, Shire
Joshua S. Jacobs, MD – Supported/Contracted Research: AstraZeneca, Biocryst, Circassia, CSL Behring, Dyax, Genentech, Merck, Novartis, Roche, Shire, Teva; Consultant/Advisor: Dyax, Novartis, Roche, Salix, Shire, Teva, Valeant; Speaker: Dyax, Merch, Novartis, Shire, Teva
Course summary
Course opens: 
Course expires: 
Please login or create an account to take this course.